Saturday, October 24, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Initiates Coverage on IDEAYA Biosciences with Buy Rating and 55 Price Target

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
Biotechnology Markets and money
0
SHARES
35
VIEWS
Share on FacebookShare on Twitter

BTIG analyst Justin Zelin has recently started covering IDEAYA Biosciences (NASDAQ: IDYA) and has given it a Buy rating with a Price Target of $55. This optimistic evaluation shows faith in the company’s future prospects. The Buy rating and price target suggest a promising forecast for IDEAYA Biosciences’ stock performance in the market.

IDYA Stock Shows Strong Performance on March 8, 2024 with Positive Price Momentum

On March 8, 2024, IDYA stock showed strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock.

IDYA shares opened at $46.27, which was $1.04 higher than its previous close. Throughout the trading day, the stock saw a price increase of $1.09, resulting in a 2.41% rise in its value. This upward movement in price reflects investor confidence and bullish sentiment towards IDYA.

IDYA Stock Sees Significant Decrease in Revenue and Net Income in 2024

On March 8, 2024, IDYA stock experienced a significant decrease in total revenue compared to the previous year and quarter. According to data from CNN Money, the company reported total revenue of $23.39 million for the past year, which represents a 54.08% decrease from the previous year. In the fourth quarter of the same year, IDYA reported total revenue of $3.92 million, marking a 51.19% decrease from the previous quarter.

Similarly, IDYA also reported a decline in net income for the past year and quarter. The company reported a net income of -$112.96 million for the past year, representing a 92.59% decrease from the previous year. In the fourth quarter, IDYA reported a net income of -$33.95 million, which remained unchanged from the previous quarter.

Furthermore, IDYA’s earnings per share (EPS) also saw a decrease compared to the previous year, but remained stable from the previous quarter. The company reported an EPS of -$1.96 for the past year, marking a 38.76% decrease from the previous year. In the fourth quarter, IDYA reported an EPS of -$0.52, which remained unchanged from the previous quarter.

Overall, IDYA stock performance on March 8, 2024, was characterized by declining total revenue and net income compared to the previous year and quarter. Investors may need to closely monitor IDYA’s financial performance and market trends to make informed decisions about their investments in the company.

Tags: IDYA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Industrial Metals and Mining stock Trading

Analysts Bullish on Gates Industrial Corporation Upgraded Rating and Price Target

Finance_ Trading ratings today (2)

FIGS Shares Decline After Oppenheimer Downgrade

Finance_Investment (2)

Truist Securities Analyst Maintains Hold Rating on Vornado Realty with Revised Price Target

Recommended

BioNTech Stock

BioNTech Investors Face Legal Challenge Following CureVac Acquisition

10 months ago
Eli Lilly Stock

Eli Lilly Faces Pricing Pressure as New Regulations Force Strategic Shift

1 year ago
MMM stock news

WestPark Capital Downgrades Palo Alto Networks to Hold Rating Despite Companys Resolute Stance

3 years ago
Inmune Bio Stock

Inmune Bio Navigates Strategic Shift Amid Market Pressures

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Most Stocks Rose While the Index Fell: Earnings Week Is the Test

Tesla Jumps on a Roadster as Tech Slips Into the Weekend

CoreWeave’s Bonds Flash Red as Strong Earnings Fall Flat

Hot Core CPI Sorts the Stocks: ASML Delivers, J&J Stumbles

Goldman Delivers as Memory Stocks Slide Ahead of CPI

Optics Run Hot as Chip Leaders Pause for Breath

Trending

Bitcoin Stock
Newsletter

Lam, Tesla and Meta Clear the Bar and Still Get Sold

by Stephanie Dugan
October 22, 2026
0

Dear readers, Wednesday's open question got its answer overnight. Lam Research told investors that global spending on...

Danaher Stock

Beat Estimates, Lose Ground: Guidance Now Drives Earnings Season

October 21, 2026
Mastercard Stock

The AI Rally Needs Cheap Money, and Cheap Money Is Scarce

October 20, 2026
Meta Stock

Most Stocks Rose While the Index Fell: Earnings Week Is the Test

October 18, 2026
Tesla Stock

Tesla Jumps on a Roadster as Tech Slips Into the Weekend

October 16, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Lam, Tesla and Meta Clear the Bar and Still Get Sold
  • Beat Estimates, Lose Ground: Guidance Now Drives Earnings Season
  • The AI Rally Needs Cheap Money, and Cheap Money Is Scarce

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com